At the same time, future research should explore the combination of NAT10/HK2 inhibitors with existing therapies (immunotherapy, chemotherapy, targeted therapy, etc.)to improve treatment efficacy and develop biomarkers for personalized medical methods of GC. The gene discussed is NAT10; the disease is gastric cancer.